Connect with us


Senolytics, a new anti-aging therapeutic, taking on Humira and Enbrel



cancer cells
cells in tissue culture from human connective tissue, illuminated
by darkfield amplified contrast, at a magnification of


  • A new
    anti-aging therapeutic
    in the clinical pipeline could stand
    to disrupt multibillion-dollar
    legacy franchises
    like AbbVie’s Humira and Amgen’s
  • This new type of therapeutic, called
    , is being developed by four biotech companies
    right now, and analysts think the first market-ready product
    could become available as early as 2023. 
  • Senolytics will be able to target all age-related
    diseases, eliminating the need for current therapeutics that
    are more limited in the range of diseases they can

A new therapeutic treatment might be making its way to the
anti-aging market, and it could stand to disrupt
multibillion-dollar franchises like AbbVie’s Humira and Amgen’s

According to a report from analysts at Citi GPS, many biotech
companies are investing in developing senolytics, a new type of
treatment to combat all aging-related disease.

These drugmakers include Unity
, Oisin Biotechnologies, Siwa Therapeutics, and
Google venture Calico. The first commercially available
treatment could be here by 2023, according to the Citi
report, but a proof of concept could be available as early
as next year. 

senolytics pipelineCiti

Age-related diseases like cardiovascular disease, arthritis, eye
disease, and Alzheimer’s Disease affect millions of people in the
US. And in the past, pharmaceutical companies have tried
unsuccessfully to develop anti-aging therapeutics. But with new
discoveries in the field along with several proof of concept
published by scientists, with the most recent
published by Mayo Clinic in July, senolytics has been
deemed a viable field that could actually impact age-related

Read more:
potential treatments for aging could unlock cures to a range of
age-related illnesses, from cancer to heart disease

If successful, senolytics could replace the use of
therapeutics catered to specific aging-related diseases like
AbbVie’s Humira and Amgen’s Enbrel which are both approved for
numerous forms of arthritis and psoriasis, as well as Regeneron’s
Eylea, and Genetech’s Lucentis which are both approved for
age-related eye diseases. 

The market opportunity for senolytics is massive, as AbbVie’s
Humira alone is tracking to be a $21 billion drug by 2020.

Senescent cells, which are the intended targets of senolytics,
accumulate in tissues as a result of aging and stress. They have
been found to be associated with a number of age-related diseases
such as atherosclerosis, arthritis, retinal degeneration,
fibrosis, and Alzheimer’s disease and could be an underlying
cause for all of these age-related diseases.

These cells stop dividing and don’t die like normal cells do.
They can also have inflammatory effects on other cells in the
body. Senolytics work to flush these cells out of the body.
Eliminating senescent cells in animal models prevented the onset
of age-related diseases and reversed the effects of aging. 

senolytics and miceCiti

In a recent experiment conducted by Mayo Clinic, senolytics
extended mice lifespan by 36%. 

While safety still needs to be verified in humans, senolytics
appear relatively safe in animal models, with little to no side
effects other than the fact that it slows wound healing. 

Continue Reading
Advertisement Find your dream job